Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina Magrey

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Arthritis Care & Research|November 1, 2023
Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two TrialsMarina Magrey, James Cheng-Chung Wei, Arne Yndestad, et al.
ACR Open Rheumatology|April 25, 2023
The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of DiseaseMarina Magrey, Jessica A Walsh, Sandra Flierl, et al.
Rheumatology Advances in Practice|June 30, 2025
Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature reviewDenis Poddubnyy, Uta Kiltz, Abhijeet Danve, et al.
The Journal of Rheumatology|June 2, 2024
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical TrialsAtul Deodhar, Xenofon Baraliakos, Marina Magrey, et al.
Arthritis Research & Therapy|March 25, 2026
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United StatesMarina Magrey, Milena A Gianfrancesco, Lara Fallon, et al.
Rheumatology and Therapy|June 23, 2023
Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation AnalysisLars Erik Kristensen, Victoria Navarro-Compán, Marina Magrey, et al.
Advances in Therapy|July 22, 2025
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom DurationVictoria Navarro-Compán, John D Reveille, Proton Rahman, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
Rheumatology and Therapy|October 15, 2022
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 StudyIain B McInnes, Koji Kato, Marina Magrey, et al.
Rheumatology and Therapy|March 13, 2026
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS StudiesXenofon Baraliakos, Louis Bessette, Kurt de Vlam, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Arthritis Care & Research|November 1, 2023
Relationships of Work Productivity and Activity Impairment With Patient-Reported Outcomes in Ankylosing Spondylitis: Results From Two TrialsMarina Magrey, James Cheng-Chung Wei, Arne Yndestad, et al.
ACR Open Rheumatology|April 25, 2023
The International Map of Axial Spondyloarthritis Survey: A US Patient Perspective on Diagnosis and Burden of DiseaseMarina Magrey, Jessica A Walsh, Sandra Flierl, et al.
Rheumatology Advances in Practice|June 30, 2025
Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature reviewDenis Poddubnyy, Uta Kiltz, Abhijeet Danve, et al.
The Journal of Rheumatology|June 2, 2024
Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical TrialsAtul Deodhar, Xenofon Baraliakos, Marina Magrey, et al.
Arthritis Research & Therapy|March 25, 2026
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United StatesMarina Magrey, Milena A Gianfrancesco, Lara Fallon, et al.
Rheumatology and Therapy|June 23, 2023
Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation AnalysisLars Erik Kristensen, Victoria Navarro-Compán, Marina Magrey, et al.
Advances in Therapy|July 22, 2025
Ixekizumab Improves Signs, Symptoms, and Quality of Life in Patients with Axial Spondyloarthritis Irrespective of Symptom DurationVictoria Navarro-Compán, John D Reveille, Proton Rahman, et al.
Rheumatology and Therapy|February 23, 2023
Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing SpondylitisVictoria Navarro-Compán, Xenofon Baraliakos, Marina Magrey, et al.
Rheumatology and Therapy|October 15, 2022
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 StudyIain B McInnes, Koji Kato, Marina Magrey, et al.
Rheumatology and Therapy|March 13, 2026
Impact of Upadacitinib on Reducing Pain in Patients Across the Axial Spondyloarthritis Spectrum: A Post Hoc Analysis of the Phase 2/3 SELECT-AXIS StudiesXenofon Baraliakos, Louis Bessette, Kurt de Vlam, et al.
Pageof 7